Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Weili Sun, MDPhD, Paul S Gaynon, MD, Richard Sposto, PhD, Henrique Bittencourt, MD, Andrew E. Place, MDPhD, Yoav H Messinger, MD, Chris Fraser, MD, Luciano Dalla-Pozza, MD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Xiaojing Yang, PhD, Gangning Liang, PhD, Peter A. Jones, PhD DSc, Alan S. Wayne, MD, Todd Cooper, DO

Blood (2014) 124 (21): 3764.

https://doi.org/10.1182/blood.V124.21.3764.3764

Published: 2014

Journal Articles

High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.

Phoenix A. Ho, MD, Todd Alonzo, PhD, Robert B. Gerbing, M.A., Jessica A. Pollard, MD, Susana C. Raimondi, Betsy A. Hirsch, PhD, Todd Cooper, DO, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2530.

https://doi.org/10.1182/blood.V120.21.2530.2530

Published: 2012

Journal Articles

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

Y. Lucy Liu, MD, PhD, Yan Yan, MD, Shelly Y. Lensing, MS, Todd Cooper, DO, Peter D. Emanuel, MD

Blood (2012) 120 (21): 2558.

https://doi.org/10.1182/blood.V120.21.2558.2558

Published: 2012

Journal Articles

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

Lia Gore, MD, Margaret E. Macy, M.D., Francoise Mechinaud, MD, Aru Narendran, MD, PhD, Frank Alvaro, MD, Carola A.S. Arndt, MD, Phillip Barnette, MD, Jessica Boklan, MD, Todd Cooper, DO, Laura Martin, MD, W Tcheng, MD, Peter Tarassoff, MD, Mark M Jones, MD, Soheil Meshinchi, MD, PhD, Robert J. Arceci, MD, PhD

Blood (2012) 120 (21): 1517.

https://doi.org/10.1182/blood.V120.21.1517.1517

Published: 2012

Journal Articles

Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia

Aarthi Jayanthan, Todd Cooper, DO, Sandra E. Dunn, PhD, Victor A. Lewis, MD, Aru Narendran, MD, PhD

Blood (2012) 120 (21): 3573.

https://doi.org/10.1182/blood.V120.21.3573.3573

Published: 2012

Journal Articles

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

Todd Cooper, DO, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., John Perentesis, MD, James A. Whitlock, MD, Jeffrey W. Taub, MD, Terzah M. Horton, MD, PhD, Alan S. Gamis, MD, MPH, Bassem I. Razzouk, MD

Blood (2012) 120 (21): 3604.

https://doi.org/10.1182/blood.V120.21.3604.3604

Published: 2012

Journal Articles

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Todd Cooper, DO, Richard Sposto, PhD, Jeannette Cassar, Elena Eckroth, CCRC, Jemily Malvar, M.S., Paul Gaynon, MD, Steven Dubois, MD, Bill H Chang, MD, PhD, Lia Gore, MD, Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD

Blood (2012) 120 (21): 3605.

https://doi.org/10.1182/blood.V120.21.3605.3605

Published: 2012

Journal Articles

Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group

Todd A. Alonzo, PhD, Phoenix A. Ho, MD, Robert B. Gerbing, MA, Alan S. Gamis, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Todd Cooper, DO, Janet Franklin, MD, MPH, Laura Pardo, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2010) 116 (21): 761.

https://doi.org/10.1182/blood.V116.21.761.761

Published: 2010

Journal Articles

Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

Nobuko Hijiya, MD, Jo-Anne Paul, Michael J. Borowitz, MD, PhD, Blythe Thomson, MD, Michael Isakoff, MD, Lewis B. Silverman, MD, Peter G Steinherz, MD, Richard Kadota, MD, Joseph G Pressey, MD, Violet Shen, MD, Roland Chu, MD, Todd Cooper, DO, Sima Jeha, MD, Bassem I. Razzouk, MD, Michael E. Rytting, MD, Elly Barry, MD, MMSc, William L. Carroll, MD, Paul Gaynon, MD

Blood (2010) 116 (21): 866.

https://doi.org/10.1182/blood.V116.21.866.866

Published: 2010

Journal Articles

Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group

Soheil Meshinchi, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Phoenix A. Ho, MD, Alan S. Gamis, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Todd Cooper, DO, Janet Franklin, MD, MPH, Laura Pardo, Michael R. Loken, PhD

Blood (2010) 116 (21): 1702.

https://doi.org/10.1182/blood.V116.21.1702.1702

Published: 2010

Journal Articles

CD20 up-Regulation In Induction Therapy for Childhood B Lymphoblastic Leukemia

Tanya C. Watt, MD, MSc, Sunita Park, MD, Todd Cooper, DO

Blood (2010) 116 (21): 2124.

https://doi.org/10.1182/blood.V116.21.2124.2124

Published: 2010

Journal Articles

AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells.

Shamim Lotfi, MS, Aarthi Jayanthan, BS, Victor A. Lewis, MD, Greg Guilcher, MD, Matthew S Squires, PhD, Todd Cooper, DO, Aru Narendran, MD., Ph.D

Blood (2009) 114 (22): 3078.

https://doi.org/10.1182/blood.V114.22.3078.3078

Published: 2009

Journal Articles

AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.

Todd Cooper, DO, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, John Perentesis, James A. Whitlock, MD, Elizabeth Raetz, MD, William L. Carroll, MD, Alan S. Gamis, MD, B. I. Razzouk

Blood (2009) 114 (22): 3076.

https://doi.org/10.1182/blood.V114.22.3076.3076

Published: 2009

Journal Articles

Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia

Nobuko Hijiya, MD, Paul S. Gaynon, MD, Manuel Fernandez, Lewis B. Silverman, MD, Blythe Thomson, MD, Roland Chu, Todd Cooper, DO, Richard Kadota, MD, Michael Rytting, M.D., Peter G. Steinherz, MD, Violet Shen, Sima Jeha, MD, Elly Barry, MD, William L. Carroll, MD

Blood (2008) 112 (11): 2925.

https://doi.org/10.1182/blood.V112.11.2925.2925

Published: 2008

NARROW

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group

Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group

CD20 up-Regulation In Induction Therapy for Childhood B Lymphoblastic Leukemia

AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells.

AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.

Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only